2023. Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s112. DOI:https://doi.org/10.25251/skin.7.supp.112.